Trial Profile
p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer a Phase II Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2023
Price :
$35
*
At a glance
- Drugs Cancer vaccine-p53 (Primary) ; Cyclophosphamide
- Indications Ovarian cancer
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms ISA-p53-CTX
- 07 Feb 2014 New source identified and integrated.Netherlands Trial Register
- 24 Feb 2011 Actual end date (July 2009) added as reported by ClinicalTrials.gov.
- 24 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.